cancer vaccine News
-
OncoImmunity will start collaborating with a US-based neoantigen specific T-cell therapy company
OncoImmunity announced today the signing of a collaboration agreement with a T cell therapy company based in the US . The companies will cooperate to access the predictive capabilities of OncoImmunity's artificial intelligence platform called the Immuneoprofiler™ to identify immunogenic neoantigens for the US partner’s T-cell platform. The collaboration agreement marks the increasing ...
-
OncoImmunity starts a personalized cancer vaccine project with a Chinese biotech company
OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients. The collaboration will demonstrate the power of the ...
-
Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that its CEO, Pierre Belichard, will provide a company update (in person) at the Jefferies Healthcare Conference in New York City, US which will take place June 8-10, 2022. In his presentation, Dr. Belichard will provide an ...
By Enterome
-
Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like complexes that can ...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
By Enterome
-
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The ...
By Transgene
-
NEC OncoImmunity publishes a unique HLA typing technology that discovers new HLA alleles, and tumor specific HLA alleles
The computational approach performs HLA typing from next generation sequencing data by using the current strengths of conventional HLA typing while simultaneously allowing for the discovery of novel HLA alleles and tumor-specific HLA variants, through leveraging proprietary mutation calling bioinformatics at NOI. NOI collaborated with Ultimovacs ASA in the study to validate the HLA typing ...
-
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy: Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen targets. Early signs of clinical activity were observed with ...
By Transgene
-
Cancer Vaccine Start Up, Calviri, Closes Successful Seed Funding
Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on ending deaths from cancer, today announced the closing of $2.25 million in seed round funding. The funding is from five private investors including Dr. Jacque Sokolov, a Calviri Board member, and Dr. Mitzi Krockover. Calviri was founded based on the discovery that tumors make frequent and ...
By Calviri
-
Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer
biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company. Ramy joins from the Parker Institute for Cancer Immunotherapy where he was Chief Medical Officer and will remain on the board. At the Parker Institute, he ...
By bit.bio
-
AIVITA Biomedical CEO Dr. Hans Keirstead to Give Keynote Address at Advanced Therapies Congress in London
IRVINE, Calif. – Oct. 4, 2021 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chairman and CEO Dr. Hans S. Keirstead will deliver a keynote address at the Advanced Therapies Congress & Expo in London, taking place October 5-6. Dr. Keirstead will speak at the following time and location: Keynote: Cell-based ...
-
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19
Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use its proprietary recombinant overlapping peptide (ROP) technology to develop a new vaccine and diagnostic tests for Covid-19. The research will be carried out in collaboration with the renowned Nuffield Department of Medicine (NDM) at the University of ...
-
Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation
The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. The largest interventional trial in dogs, it is sponsored by the Open Philanthropy Project, with additional support from Calviri, Inc., a biotech spinout from Arizona State University. The VACCS trial intends to enroll up to ...
By Calviri
-
Calviri Demonstrates That RNA Processing Errors Are a Rich Source of Tumor Neoantigens for Cancer Vaccines
Calviri, Inc., a biotech startup spun out of Arizona State University Biodesign Institute, focused on prevention and treatment of cancer, announced results that demonstrate the potential of a prophylactic vaccine against cancer. The study of RNA processing errors in tumors highlighted that a large number of frameshift neoantigens are produced. This new class of neoantigens are shown to be ...
By Calviri
-
Taiwan Vaccine Adjuvant Pioneer ImmunAdd to Attend 2022 BIO International Convention in San Diego
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ImmunAdd is undertaking the development of IA-05 in collaboration with several biopharma ...
-
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Corporation ...
-
NEC and OncoImmunity AS combine forces to use AI to empower personalized cancer immunotherapy
OncoImmunity AS today announced that it has been acquired by NEC Corporation, the renowned Japanese IT and network company, that recently launched its Artificial Intelligence (AI) driven drug discovery business. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, develops software that identifies neoantigen ...
-
Calviri Completes Enrollment of 800 Dogs in a Preventative Cancer Vaccine Trial
The double-blinded trial is testing Calviri’s vaccine aimed at broadly preventing cancers in dogs. The VACCS just completed year three of the planned five year trial. It is being conducted at three leading canine oncology centers – the Flint Animal Cancer Center at Colorado State University, the School of Veterinary Medicine at University of Wisconsin-Madison and the University of ...
By Calviri
-
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, ...
-
ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today provided an update on the development strategy for oncolytic virus ParvOryx, a wild type rat oncolytic parvovirus (H-1PV). So far, two Phase I/IIa clinical trials in recurrent glioblastoma (rGBM) and metastatic, inoperable pancreatic cancer have been completed successfully. Moreover, in a follow-up ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you